ORMP - オラメド・ファ―マシュ―ティカルズ (Oramed Pharmaceuticals Inc.) オラメド・ファ―マシュ―ティカルズ

 ORMPのチャート


 ORMPの企業情報

symbol ORMP
会社名 Oramed Pharmaceuticals Inc (オラメド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product an orally ingestible insulin capsule in phase II clinical trials is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801 Oral insulin capsule; ORMD 0901 Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.   オラメド・ファ―マシュ―ティカルズは、イスラエルの製薬会社。経口投与ソリュ―ションの開発を手掛ける。糖尿病治療用経口インスリンをはじめ、他の薬剤やワクチンの投与ソリュ―ションも開発する。主な製品は、経口インスリンカプセル剤の「ORMD-0801」や経口エクセナチドカプセルの「ORMD-0901」。本社はエルサレム。   Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
本社所在地 142 W. 57th Street New York NY 10019 USA
代表者氏名 Kevin L. Rakin ケヴィン・L・ラッキン
代表者役職名 Chairman of the Board Independent Director
電話番号 +972 2-566-0001
設立年月日 37347
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 14人
url www.oramed.com
nasdaq_url https://www.nasdaq.com/symbol/ormp
adr_tso
EBITDA EBITDA(百万ドル) -13.22500
終値(lastsale) 4.7
時価総額(marketcap) 81604290.5
時価総額 時価総額(百万ドル) 74.13837
売上高 売上高(百万ドル) 2.45000
企業価値(EV) 企業価値(EV)(百万ドル) 50.76537
当期純利益 当期純利益(百万ドル) -12.49700
決算概要 決算概要 BRIEF: For the nine months ended 31 May 2018 Oramed Pharmaceuticals Inc. revenues remained flat at $1.8M. Net loss increased 26% to $9.8M. Revenues reflect market conditions. Higher net loss reflects RESEARCH AND DEVELOPMENT EXPENSES increase of 19% to $9.2M (expense) GENERAL AND ADMINISTRATIVE EXPENSES increase of 67% to $3.1M (expense) FINANCIAL EXPENSES increase of 11% to $72K (expense).

 ORMPのテクニカル分析


 ORMPのニュース

   Oramed Pharmaceuticals : Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients | MarketScreener  2020/09/15 12:26:04 MarketScreener
NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. , a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results… | September 15, 2020
   Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients  2020/09/15 12:25:00 Benzinga
NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm. The survey included qualitative interviews with healthcare providers as well as type 1 (T1D) and type 2 (T2D) diabetes patients regarding Oramed's lead oral insulin product, ORMD-0801, which is headed into a Phase III trial. Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed. There was strong support among these health care providers for use of oral insulin with T2D patients early in the treatment process through a primary care physician before the need for injectable insulin and before the patient is moved to an endocrinologist for diabetes care.
   Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin  2020/07/15 12:55:00 Benzinga Feeds
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidron said, "We are very pleased with the results of our meeting with the FDA and look forward to submitting our finalized protocols for the Phase 3 trials to the FDA. Following successful Phase 3 trials, we would submit the BLA, which when approved would grant a full 12 years of marketing exclusivity for ORMD-0801.
   Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin  2020/06/15 12:25:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801…
   Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June  2020/05/05 11:55:00 PR Newswire
NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Association…
   Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin  2020/07/15 12:55:00 Benzinga Feeds
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidron said, "We are very pleased with the results of our meeting with the FDA and look forward to submitting our finalized protocols for the Phase 3 trials to the FDA. Following successful Phase 3 trials, we would submit the BLA, which when approved would grant a full 12 years of marketing exclusivity for ORMD-0801.
   Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin  2020/06/15 12:25:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801…
   Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June  2020/05/05 11:55:00 PR Newswire
NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Association…
   Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock  2020/02/26 21:05:00 PR Newswire
NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and sell shares of its common stock in an…
   Oramed Patent in Europe to be Granted for Oral Delivery of Proteins  2020/01/28 12:25:00 PR Newswire
NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has indicated its intent…
   Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin  2020/07/15 12:55:00 Benzinga Feeds
NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidron said, "We are very pleased with the results of our meeting with the FDA and look forward to submitting our finalized protocols for the Phase 3 trials to the FDA. Following successful Phase 3 trials, we would submit the BLA, which when approved would grant a full 12 years of marketing exclusivity for ORMD-0801.
   Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin  2020/06/15 12:25:00 PR Newswire
NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801…
   Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June  2020/05/05 11:55:00 PR Newswire
NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Association…
   Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock  2020/02/26 21:05:00 PR Newswire
NEW YORK, Feb. 26, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it intends to offer and sell shares of its common stock in an…
   Oramed Patent in Europe to be Granted for Oral Delivery of Proteins  2020/01/28 12:25:00 PR Newswire
NEW YORK, Jan. 28, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) and (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has indicated its intent…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オラメド・ファ―マシュ―ティカルズ ORMP Oramed Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)